These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 2005218)

  • 1. Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle.
    Fluker MR; Marshall LA; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1991 Apr; 72(4):912-9. PubMed ID: 2005218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (detirelix).
    Marshall LA; Fluker MR; Jaffe RB; Monroe SE
    J Clin Endocrinol Metab; 1991 Apr; 72(4):927-33. PubMed ID: 2005220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM; Nestor JJ; Vickery BH
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition.
    Kettel LM; Roseff SJ; Chiu TC; Bangah ML; Vale W; Rivier J; Burger HG; Yen SS
    J Clin Endocrinol Metab; 1991 Sep; 73(3):644-9. PubMed ID: 1908486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
    Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human.
    Hall JE; Bhatta N; Adams JM; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1991 May; 72(5):993-1000. PubMed ID: 1902489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of treatment with an LHRH antagonist on the ovulatory cycle are reduced when administered during the late follicular phase.
    Fraser HM
    Contraception; 1990 Jan; 41(1):73-83. PubMed ID: 2105873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe.
    Mais V; Kazer RR; Cetel NS; Rivier J; Vale W; Yen SS
    J Clin Endocrinol Metab; 1986 Jun; 62(6):1250-5. PubMed ID: 3084538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function.
    Zelinski-Wooten MB; Lanzendorf SE; Wolf DP; Chandrasekher YA; Stouffer RL
    J Clin Endocrinol Metab; 1991 Sep; 73(3):577-83. PubMed ID: 1908481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corpus luteum insufficiency induced by a rapid gonadotropin-releasing hormone-induced gonadotropin secretion pattern in the follicular phase.
    Soules MR; Clifton DK; Bremner WJ; Steiner RA
    J Clin Endocrinol Metab; 1987 Sep; 65(3):457-64. PubMed ID: 3114301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiation of high dose gonadotrophin-releasing hormone antagonist treatment during the late follicular phase in the macaque abolishes luteal function irrespective of effects upon the luteinizing hormone surge.
    Fraser HM; Lunn SF; Morris KD; Deghenghi R
    Hum Reprod; 1997 Mar; 12(3):430-5. PubMed ID: 9130734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development.
    Welt CK; Adams JM; Sluss PM; Hall JE
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2163-9. PubMed ID: 10372726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic changes in circulating inhibin levels during the luteal-follicular transition of the human menstrual cycle.
    Roseff SJ; Bangah ML; Kettel LM; Vale W; Rivier J; Burger HG; Yen SS
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1033-9. PubMed ID: 2507568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.